Apr 17 |
Allarity Therapeutics receives Nasdaq-approved extension to regain compliance
|
Apr 17 |
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
|
Apr 15 |
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
|
Apr 12 |
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
|
Apr 5 |
Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket
|
Apr 4 |
Allarity Therapeutics to implement 1-for-20 reverse stock split
|
Apr 4 |
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
|
Mar 27 |
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
|
Mar 25 |
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
|
Mar 8 |
Allarity Therapeutics GAAP EPS of -$10.26
|